#USA #Boston #biotechnology #Ginkgo Bioworks #DNA

Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) continues to establish itself as a leader in cell programming and biosecurity. On August 7, 2025, the company announced its financial results for the second quarter of 2025, reflecting a mix of growth in certain areas and challenges in others. This report encapsulates their performance, strategic initiatives, and future outlook.

Financial Highlights

During the second quarter of 2025, Ginkgo reported a total revenue of $50 million, a decline from the $56 million recorded in the same period last year. Notably, the revenue from Cell Engineering grew to $39 million, marking an 8% increase from $36 million in Q2 2024, largely credited to rising demand from biopharma and government contracts. However, Biosecurity revenue deteriorated to $10 million from $20 million year-over-year.

The company's GAAP net loss for the second quarter was $(60) million, a significant improvement from the $(217) million loss in Q2 2024. Additionally, the adjusted EBITDA loss narrowed to $(28) million from $(99) million, supported by a steady reduction in operating expenses. As of June 30, 2025, Ginkgo reported a cash balance of $474 million, positioning it favorably for upcoming projects and R&D.

Strategic Focus on Automation and Innovation

Ginkgo has identified its platform as a pivotal force for artificial intelligence in biology, subsequently accelerating its automation offerings and their capabilities. A remarkable milestone was achieved when the Pacific Northwest National Laboratory chose Ginkgo to provide state-of-the-art automated anaerobic phenotyping. This contract is projected to be the largest automated system focused on anaerobic research globally, emphasizing Ginkgo's growth in biotechnology applications.

Simultaneously, Ginkgo launched a new in vitro ADME profiling service based on their proprietary automation system. This service aims to enhance operational efficiency and decrease costs drastically by automating traditionally labor-intensive assays, allowing clients to conduct more comprehensive profiling earlier in the drug development process. Furthermore, Ginkgo has introduced its first direct-to-scientist product: an E. coli-based cell-free protein synthesis system designed for optimal performance and compatibility with automated systems.

Progress and Future Outlook

Ginkgo continues to reaffirm its commitment to achieving adjusted EBITDA breakeven by the end of 2026, actively reporting $250 million in annualized cost reductions achieved three months ahead of schedule through various measures, including workforce reductions and consolidations of workspace.

For the full year 2025, Ginkgo expects total revenue to range between $167 million and $187 million, with Cell Engineering revenue projected at $117 million to $137 million, and Biosecurity revenue anticipated to reach at least $40 million.

Conference Call and Investor Engagement

A videoconference was held on August 7, 2025, further explaining their Q2 results, strategic updates, and future expectations, allowing investors to engage through question submissions ahead of the session. The company continues to engage with its investors through various platforms, reinforcing transparency and collaboration.

In summary, Ginkgo Bioworks remains at the forefront of biotechnology innovation as it navigates its financial landscape and expands its operational capacities, showcasing resilience and strategic foresight in a dynamic market.